Literature DB >> 24900683

Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.

Cristian Ochoa-Puentes1, Stefanie Bauer2, Matthias Kühnle2, Günther Bernhardt2, Armin Buschauer2, Burkhard König3.   

Abstract

Recently reported compounds such as UR-COP78 (6) are among the most potent and selective ABCG2 modulators known so far but are prone to rapid enzymatic cleavage at the central benzanilide moiety. In search for more stable analogues, according to a bioisosteric approach, a series of N-(biphenyl-3-yl)quinoline carboxamides was prepared by solid phase and solution phase synthesis. The biphenyl moiety was constructed by Suzuki coupling. Inhibition of ABCB1 and ABCG2 was determined in a calcein-AM and a Hoechst 33342 microplate assay, respectively. Most synthesized compounds selectively inhibited the ABCG2 transporter at submicromolar concentrations with a maximal inhibitory effect (I max) over 90% (e.g., UR-COP228 (22a), IC50 591 nM, I max 109%; UR-COP258 (31), IC50 544 nM, I max 112%), though with lower potency and selectivity than 6. The biphenyl analogues are considerably more stable and demonstrate that the benzanilide core is not a crucial structural feature of quinoline carboxamide-type ABCG2 modulators.

Entities:  

Keywords:  ABC transporter; MCF-7 cells; Suzuki coupling; breast cancer resistance protein; solid phase synthesis

Year:  2013        PMID: 24900683      PMCID: PMC4027546          DOI: 10.1021/ml4000832

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  13 in total

1.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

Authors:  M de Bruin; K Miyake; T Litman; R Robey; S E Bates
Journal:  Cancer Lett       Date:  1999-11-15       Impact factor: 8.679

2.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

3.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

4.  Antiproliferative agents that interfere with the cell cycle at the G1-->S transition: further development and characterization of a small library of stilbene-derived compounds.

Authors:  Daniela Pizzirani; Marinella Roberti; Andrea Cavalli; Stefania Grimaudo; Antonietta Di Cristina; Rosaria Maria Pipitone; Nicola Gebbia; Manlio Tolomeo; Maurizio Recanatini
Journal:  ChemMedChem       Date:  2008-02       Impact factor: 3.466

5.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.

Authors:  S K Rabindran; D D Ross; L A Doyle; W Yang; L M Greenberger
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

6.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

7.  Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2).

Authors:  Cristian Ochoa Puentes; Peter Höcherl; Matthias Kühnle; Stefanie Bauer; Kira Bürger; Günther Bernhardt; Armin Buschauer; Burkhard König
Journal:  Bioorg Med Chem Lett       Date:  2011-04-28       Impact factor: 2.823

Review 8.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

Authors:  Pauline Breedveld; Jos H Beijnen; Jan H M Schellens
Journal:  Trends Pharmacol Sci       Date:  2005-12-05       Impact factor: 14.819

9.  Pheophorbide a is a specific probe for ABCG2 function and inhibition.

Authors:  Robert W Robey; Kenneth Steadman; Orsolya Polgar; Kuniaki Morisaki; Margaret Blayney; Prakash Mistry; Susan E Bates
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

Review 10.  Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.

Authors:  B Han; J-T Zhang
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-01
View more
  4 in total

1.  Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators.

Authors:  Diana Peña-Solórzano; Matthias Scholler; Günther Bernhardt; Armin Buschauer; Burkhard König; Cristian Ochoa-Puentes
Journal:  ACS Med Chem Lett       Date:  2018-07-25       Impact factor: 4.345

2.  ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning.

Authors:  Dejun Jiang; Tailong Lei; Zhe Wang; Chao Shen; Dongsheng Cao; Tingjun Hou
Journal:  J Cheminform       Date:  2020-03-05       Impact factor: 5.514

Review 3.  More Than Resveratrol: New Insights into Stilbene-Based Compounds.

Authors:  Paulina Pecyna; Joanna Wargula; Marek Murias; Malgorzata Kucinska
Journal:  Biomolecules       Date:  2020-07-27

4.  Using Jupyter Notebooks for re-training machine learning models.

Authors:  Aljoša Smajić; Melanie Grandits; Gerhard F Ecker
Journal:  J Cheminform       Date:  2022-08-13       Impact factor: 8.489

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.